pfizer inc fda flags drug ad over claims omissions reuters a pfizer inc ad for geodon omitted important risk information and contained unsupported claims that the schizophrenia drug was better than another drug regulators said the food and drug administration asked pfizer to drop the ad which ran in a medical journal the agencys letter to the drug maker was dated july but posted on the fda web site yesterday the fda said the ad included some information about potential side effects from injectable geodon but failed to list "other serious warnings and precautions " specifically the promotion failed to mention the possibility of neuroleptic malignant syndrome tardive dyskinesia high blood sugar and diabetes a pfizer spokeswoman couldnt be reached to comment 
